Abstract 4687
Background
Small RNAs are multiple classes of short non-coding RNAs (ncRNAs) that include microRNAs (miRNAs), transfer RNA fragments (tRFs), and other ncRNA fragments that play essential role in gene regulation. Small RNAs exist in blood circulation within extracellular vesicles (EVs), which have been the center of the attention at cell-to-cell communication tools, or bound to proteins or lipid. Recent studies have shown that the expression levels of small RNAs are different between patients with breast cancer (BC) and cancer-free individuals. Thus, circulating small RNAs have attracted as valuable biomarkers for cancer detection.
Methods
First, we assessed and the expression level of circulating small RNAs in the serum of BC patients (n = 78) and cancer-free volunteers (control) (n = 72) using next generation sequencer. By comparing those expression level, we identified some small RNAs that have signifficant difference between 2 groups as biomarker candidates for BC detection. We constructed a diagnostic model using some small RNAs from biomarker candidates. To test the possibilities that those candidates are released from cancer cells, we next profiled small RNAs within EVs that isolated from the serum of participants in this study and from breast cancer cells (MCF-7 and MDA-MB-231) and normal epithelial cells (184-h TERT).
Results
Twelve circulating small RNAs that expressed significantly higher in BC patients compared to control were identified, indicating potential biomarkers for BC detection. A diagnostic model using 4 small RNAs including isoforms of miRNAs (isomiRs) and tRFs was. The ROC curve analysis revealed that our model showed a high diagnostic accuracy of AUC 0.945 and achieved discriminating stage 0 BCs from control. Importantly, significantly different expression in serum-EVs was observed in 4 small RNAs between BC patients and control. Furthermore, 4 small RNAs were also observed in EVs derived from cell culture media in breast cancer cells and normal epithelial cells and those expressions were aberrant as the same as those of serum-EVs.
Conclusions
These findings suggests circulating small RNAs in serum serve as potential biomarkers for BC detection that enables to include the molecular movement of cancer cells.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hidetoshi Tahara.
Funding
Has not received any funding.
Disclosure
H. Tahara: Advisory / Consultancy: MiRTeL.
Resources from the same session
5694 - Findings from a new specialist remote Counselling Service for Neuroendocrine Neoplasm (NEN) patients and family members
Presenter: Catherine Bouvier
Session: Poster Display session 2
Resources:
Abstract
4725 - Hematologic malignancies in temozolomide-treated metastatic pancreatic neuroendocrine tumors
Presenter: Nicole Balmaceda
Session: Poster Display session 2
Resources:
Abstract
5842 - Efficacy and toxicity of combination chemotherapy with cyclophosphamide, vincristine and an anthracycline in patients with metastatic extrapulmonary neuroendocrine carcinoma
Presenter: Leonidas Apostolidis
Session: Poster Display session 2
Resources:
Abstract
1543 - An Australian multi-centre experience of the use of peptide receptor radionuclide therapy for bronchial carcinoid tumours.
Presenter: Lisi Lim
Session: Poster Display session 2
Resources:
Abstract
4175 - Extra-pulmonary (EP) high grade (HG) neuroendocrine carcinoma (NEC): real-life outcomes of fifty-eight patients from a Portuguese cancer center.
Presenter: Rita Conde
Session: Poster Display session 2
Resources:
Abstract
3274 - Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNET)
Presenter: Shira Sherman
Session: Poster Display session 2
Resources:
Abstract
3534 - HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
Presenter: Milton Barros
Session: Poster Display session 2
Resources:
Abstract
2137 - Clinical utility of Metabolic Tumor Volume in Papillary Thyroid Carcinoma
Presenter: Norihiko Takemoto
Session: Poster Display session 2
Resources:
Abstract
3864 - Correlation of thyroglobulin (Tg) oscillations with progression-free survival (PFS) in patients with radioactive iodine-refractory (RAI-R) differentiated thyroid carcinoma (DTC) treated with multikinase inhibitors (MKI).
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract
2820 - Analytical validation of a thyroid cancer diagnostic method based on the relative quantification of CLDN10, HMGA2 and LAMB3 expression
Presenter: Mateus Barrosfilho
Session: Poster Display session 2
Resources:
Abstract